AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

20.150

-2.380-10.56%

Volume:796.02K

Turnover:16.87M

Market Cap:2.55B

PE:86.59

High:22.920

Open:22.500

Low:20.150

Close:22.530

52wk High:23.760

52wk Low:11.000

Shares:126.64M

Float Shares:108.39M

Volume Ratio:1.33

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.233

EPS(LYR):0.233

ROE:8.67%

ROA:3.66%

PB:7.54

PE(LYR):86.59

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-1.06%

Capital Flow

Inflow:

Outflow:

News

Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million

THOMSON REUTERS

Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug

MT Newswires Live

Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketb.com/stock/NEU.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"NEU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":20.15,"timestamp":1787724720000,"preClose":22.53,"halted":0,"volume":796019,"delay":0,"changeRate":-0.10563692853972492,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":108394581,"shares":126639526,"eps":0.2327,"marketStatus":"Not Yet Opened","change":-2.38,"latestTime":"08-26 16:12:00 AEST","open":22.5,"high":22.92,"low":20.15,"amount":16868806,"amplitude":0.122947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2327,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":22.53,"openAndCloseTimeList":[[1787702400000,1787724000000]],"volumeRatio":1.332498699907531,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NEU.AU","preClose":20.15,"auctionPrice":20.48,"auctionVolume":1766,"auctionTime":1787785207251,"referenceTime":1787740203093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787785207251}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":108394581,"roa":"3.66%","roe":"8.67%","lyrEps":0.2327,"volumeRatio":1.332498699907531,"shares":126639526,"dividePrice":0,"high":22.92,"amplitude":0.122947,"preClose":22.53,"low":20.15,"week52Low":11,"pbRate":"7.54","psRate":"39.47","week52High":23.76,"institutionHeld":0,"latestPrice":20.15,"eps":0.2327,"divideRate":0,"volume":796019,"delay":0,"ttmEps":0.2327,"open":22.5,"prevYearClose":18.61,"prevWeekClose":22.46,"prevMonthClose":18,"prevQuarterClose":17.75,"fiveDayClose":22.85,"twentyDayClose":17.13,"sixtyDayClose":13.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NEU.AU","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-16","defaultRemindTime":1789430400000,"name":"NEUREN PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-07","payableDate":"2026-09-16","currency":"AUD","dateTimestamp":1789394400000,"payDate":"2026-10-07"},{"date":"2026-08-26","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2026-09-15","recordDate":"2026-09-16","paymentDate":"2026-10-07","value":0.15,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662763421","title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763421?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704117,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684667","title":"Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:27","pubTimestamp":1787700422,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXQDJSS5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204730","title":"Neuren Says Exclusive Global Licensee Secures European Commission Marketing Authorization for Neurodevelopmental Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 08:10","pubTimestamp":1787616632,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said the European Commission gave marketing authorization for Daybu, or trofinetide, for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older to its exclusive global licensee for trofinetide, Acadia Pharmaceuticals, according to a Tuesday Australian bourse filing.Daybu is now authorized to be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, per the filing.Under the companies' license agreement, for Europe, Neuren is entitled to receive $35 million following first commercial sale, potential sales milestone payments of up to $170 million on achievement of escalating annual net sales thresholds, and tiered royalties from mid-teens to low-20s percentage of net sales.Acadia earlier said that a commercial launch in Germany is expected in the December quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","EPV","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662019942","title":"Neuren Pharmaceuticals - European Commission Grants Marketing Authorization for Daybu (Trofinetide)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662019942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662019942?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:31","pubTimestamp":1787610678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUEC7XGBB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NEU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.010578}]}}